OBJECTIVES: Ovarian cancer is considered a rare disease but with a high mortality rate in women. Among women is the 5th most common cancer in Spain and the 2nd most frequent gynecological malignant tumour. With a prevalence of 0.011% and a 0.007% incidence, it is the sixth leading cause of cancer death when compared to all other cancers and the second of the gynecological cancer in Spain. The OvarCost study’s main objective is to estimate ovarian cancer’s burden of disease in Spain.  The study’s secondary objective is to carry out a literature review regarding the disease. METHODS: A Markov model was executed via the social perspective (direct, health and non-health related, and indirect costs) within a 10 year time horizon while taking into account disease prevalence, incidence and mortality.  The model focused on epithelial ovarian cancer, and all four disease stages were taken into account. The data resulted from a literature review, later validated via a Delphi round and a physical meeting with an ovarian cancer multidisciplinary expert panel. RESULTS: The total cost of cancer in Spain is 9,258 million euros, of which 4,224MM correspond to direct health costs (46%) and 5,033MM (54%) to direct costs not related to health and indirect costs.  Thus, given this data and taking into account prevalence data at 1 and 5 years, where ovarian cancer accounted for 1.5% and 1.4%, respectively, of total cancers in Spain, our model’s results theoretically should range from 138-631 million euros, respectively.  Prevalence is 2,633 and 9,322 patients for 1 and 5 years, respectively.  These results amount to a cost per patient should range between 52,061 to 67,684 euros. CONCLUSIONS: Ovarian cancer is a significant burden to the national health system and to society as a whole. The model’s results should provide a more precise quantification of both impacts.